JasonBlairLittenMD
Pediatric Hematology & Oncology • Poway, CAChief Medical Officer - Chimeric Therapeutics
Dr. Litten is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
15023 Huntington Gate Dr92064
Poway, CA 92064Phone+1 415-802-4360- Is this information wrong?
Education & Training
University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of Miami/Jackson Health SystemResidency, Pediatrics, 2002 - 2005
Emory University School of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2020 - 2024
Clinical Trials
Publications & Presentations
PubMed
- 19 citationsPhase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular CarcinomaGhassan K. Abou-Alfa, Jean-Frédéric Blanc, Steven A. Miles, Tom M. Ganten, Jörg Trojan, Jonathan Cebon, Andre K. D. Liem, Lara Lipton, Charu Gupta, Benjamin Wu, Michae...> ;The Oncologist. 2017 Jul 1
- 2 citationsCorrections to “Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors”J-C. Soria, F. Debraud, Ratislav Bahleda, B. Adamo, Fabrice Andre, Rodrigo Dienstmann, Angelo Delmonte, Roberta Cereda, Jeffrey D. Isaacson, Jason B. Litten, Andrew R....> ;Annals of Oncology. 2015 Feb 1
- 137 citationsPhase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsJean-Charles Soria, F. Debraud, Ratislav Bahleda, B. Adamo, Fabrice Andre, R. Dientsmann, Angelo Delmonte, Roberta Cereda, Jeffrey D. Isaacson, Jason B. Litten, Andrew...> ;Annals of Oncology. 2014 Nov 1
- Join now to see all
Press Mentions
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell LymphomasDecember 7th, 2020
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat CancerJune 26th, 2020- Natural Killer Biotech Artiva Launches with $78M, Industry VeteransJune 26th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
